Deep Longevity, the company developing a broad range of biomarkers of aging to maintain physical health and wellness, restore youthfulness, and improve mental health and well-being, today announced the launch of its MindAge psychological aging clocks and the formation of a Science Advisory Board (SAB).
The MindAge tests are now available via the Deep Longevity website and via the Young.AI iPhone app available in the Apple Appstore. It builds on the recently published paper titled “PsychoAge and SubjAge: Development of Deep Biomarkers of Psychological and Subjective Age Using Artificial Intelligence”.
The new survey-based MindAge test is available at https://www.young.ai/mind-age.
The science advisory board includes some of the most outstanding and credible researchers and medical doctors in the field working in the nascent field of longevity biotechnology and longevity medicine.
The advisory board is comprised of:
Eric Verdin, MD, CEO of the Buck Institute for Research on Aging
Daniel Kraft, MD, Standord & Harvard trained physician-scientist. Founder of Exponential Medicine. Chair, XPrize Pandemic Alliance Task force
Morten Scheibye-Knudsen, MD, PhD, head of the biology of aging laboratory and professor at the University of Copenhagen
Vadim Gladyshev, PhD, professor, Head of the Gladyshev Laboratory at Harvard University
Wei-Wu He, PhD, Chairman of Human Longevity, Inc
The SAB will be chaired by the Chief Longevity Officer (CLO) of Deep Longevity, Alex Zhavoronkov, PhD, also the founder and CEO of Insilico Medicine and adjunct professor at the Buck Institute for Research on Aging.
The science advisory board will help direct and review the company’s work in the development and applications of deep biomarkers of human aging.
The chairman of the board of directors of Endurance RP, and the founder of the London Longevity Week and The Longevity Forum, Jim Mellon, commented:
“The scientific advisors of Deep Longevity are some of the highest-impact scientists, medical doctors, and most well-known experts in longevity. Under their leadership and supervision, the company will continue developing and commercializing the biological and psychological aging clocks and engaging in research with the academic and medical institutions as well as with the insurance companies worldwide”.
“Productive longevity is the most important asset we have in this life and Deep Longevity is dedicated to the measurement of aging at every level from biological to psychological. I am very happy to see the company expanding into the psychology of aging as it impacts our physical and mental health and well-being and is one of the areas we can control and intervene in”, said Alex Zhavoronkov, founder and Chief Longevity Officer, of Deep Longevity and founder and CEO of Insilico Medicine.
About Deep Longevity
Deep Longevity has been acquired by Endurance Longevity (SEHK:0575.HK), a publicly-traded company. Deep Longevity is developing explainable artificial intelligence systems to track the rate of aging at the molecular, cellular, tissue, organ, system, physiological, and psychological levels. It is also developing systems for the emerging field of longevity medicine enabling physicians to make better decisions on the interventions that may slow down, or reverse the aging processes. Deep Longevity developed Longevity as a Service (LaaS)© solution to integrate multiple deep biomarkers of aging dubbed “deep aging clocks” to provide a universal multifactorial measure of human biological age. Originally incubated by Insilico Medicine, Deep Longevity started its independent journey in 2020 after securing a round of funding from the most credible venture capitalists specializing in biotechnology, longevity, and artificial intelligence. ETP Ventures, Human Longevity and Performance Impact Venture Fund, BOLD Capital Partners, Longevity Vision Fund, LongeVC, co-founder of Oculus, Michael Antonov, and other expert AI and biotechnology investors supported the company. Deep Longevity established a research partnership with one of the most prominent longevity organizations, Human Longevity, Inc. to provide a range of aging clocks to the network of advanced physicians and researchers. https://longevity.ai/
About Endurance RP (SEHK:0575.HK)
Endurance RP is a diversified investment group based in Hong Kong currently holding various corporate and strategic investments focusing on the healthcare, wellness and life sciences sectors. The Group has a strong track record of investments and has returned approximately US$298 million to shareholders in the 21 years of financial reporting since its initial public offering.
The group recently announced the change of name to Endurance RP Limited and re-branding into Endurance Longevity to focus on fertility and longevity markets in China.
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.